KB-H

KB-H is a carbocyclic nucleoside analog, specifically a derivative of thymidine, being investigated for its potential in treating bone metastatic prostate cancer. Developed by researchers at the University of South Florida, KB-H is a structural analog of the antiviral drug stavudine (KB-S). In preclinical studies, KB-H has demonstrated the ability to inhibit the progression of prostate cancer cell lines, such as DU-145 and PC-3, by inducing apoptosis. Its mechanism involves the downregulation of several pro-inflammatory and pro-metastatic cytokines, including interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-18 (IL-18), and C-X-C motif ligand-1 (CXCL-1). By modulating these factors, KB-H aims to disrupt the complex interactions between prostate cancer cells and the bone microenvironment (osteoblasts and osteoclasts), which are critical for the progression of bone metastasis.

Other names

1-((1R,4R)-4-hydroxycyclopent-2-en-1-yl)-5-methylpyrimidine-2,4(1H,3H)-dione